Vacuna Anti-Influenza

Objectives

The material operationalises Mexico’s 2014–2015 seasonal influenza vaccination effort through allocation of 32,072,096 doses among major public-sector providers, alongside a Secretaría de Salud allocation of 15,143,896 doses distributed to federal entities in four equal consignments.[1][2]Its substantive aim is to prevent influenza and limit community transmission by extending vaccination coverage among priority populations, particularly those at elevated risk of severe respiratory complications.[3]

• Prioritise vaccination for children aged 6 months to 5 years, adults aged 60 years and over, pregnant and postpartum women, health personnel, and people aged 5 to 59 years with selected risk conditions.[4][5]
• Target older adults, people with chronic disease or immunosuppression, people at increased risk of respiratory complications or aspiration, residents of rehabilitation or geriatric institutions, healthy contacts of at-risk patients, and people with morbid obesity.[3][6]
• Extend access through house-to-house delivery, fixed posts and mobile posts in defined urban areas, rural communities, dispersed populations and hard-to-reach locations.[3]
• Maintain annual influenza vaccination because circulating strains change and antibody titres decline substantially within 9 to 12 months after vaccination.[6]
• Use annual vaccine compositions aligned with World Health Organization recommendations; the listed 2014 formulation included A/California/7/2009 (H1N1), B/Brisbane/60/2008 and A/Perth/16/2009 (H3N2) strains or specified analogous strains.[3]

A March 2014 Acuerdo CONAVA identifies November as the influenza vaccination month.[7]Beyond the allocation plan, prioritised groups and delivery modalities, the supplied material does not set out a formal overarching mission, strategic framework, measurable coverage goals or document-level objectives.[1][8]

Implementation

Implementation combines centrally scheduled vaccine allocation with state-level distribution and several service-delivery modalities. The Secretaría de Salud provides annual allocations to federal entities, while vaccine supply is distributed across the Secretaría de Salud, Mexican Social Security Institute, IMSS Oportunidades, Institute of Security and Social Services for State Workers, Ministry of National Defence and Petróleos Mexicanos.[1][9]The Secretaría de Salud annual allocation of 15,143,896 units is divided into four deliveries of 3,785,974 units scheduled for 30 September, 30 October, 20 November and 10 December.[2]

• Allocate inputs by federal entity and by population or dose category, including first doses, second doses and annual boosters for children aged 6–11 months, 12–35 months and 36–59 months.[10]
• Use state-level population and registration figures to inform allocations for people aged 60 years and over, pregnant women, health personnel, people living with HIV, and people with asthma, obesity, heart disease or diabetes.[11][12]
• Provide vaccination on spontaneous demand when people attend health establishments requesting the service.[13]
• Identify susceptible people at health facilities and during community visits, with participation from organised communities and local authorities.[13]
• Use nominal censuses of children and enrolment records from older-person programmes to identify incomplete schedules and plan follow-up.[13]
• Deploy mobile brigades to locations without health facilities or permanent cold-chain capacity, using house-to-house visits or mobile posts where appropriate.[13]
• Check vaccination status during every contact with health services, including consultations, emergencies, hospitalisation, surgery, routine checks and accompaniment, to reduce missed opportunities.[13]
• Conduct intensive national actions through campaign days, mass-media communication, mobilisation of collaborating institutions and focused work in low-coverage areas.[13]

House-to-house activity is to be organised in clearly delimited areas, with maps available to vaccinators and supervisors.[3]Fixed posts may operate for limited periods at local reference points such as schools, clubs, churches and markets, supported by community mobilisation and publicity on location and opening hours.[3]Mobile posts are scheduled particularly for rural, dispersed and difficult-to-access communities.[3]

The delivery model envisages coordination among public-sector institutions, scientific and civil-society organisations, private health services, the health-services regulator, security forces, academic settings and health personnel.[3]Vaccines are inactivated split-virus or purified haemagglutinin and neuraminidase-subunit products, with some virosome-based products also identified.[3]

Safety-related operational information includes expected local reactions, infrequent systemic reactions and rare anaphylaxis, as well as contraindications relating to severe allergy and a history of Guillain-Barré syndrome.[6]Eligible vaccines may be administered simultaneously with other vaccines at different injection sites, and failure to do so is characterised as a missed opportunity for protection.[6]The material does not specify formal governance structures, reporting processes, performance indicators, coverage targets, surveillance arrangements, accountability procedures, budgets or financing sources.[9][13][6]

Monitoring & Evaluation

Monitoring and accountability arrangements are limited primarily to allocation tables, delivery schedules, nominal registers and clinical safety information; the material does not establish a formal performance-management or evaluation framework.[9][14][15][13][6]

• Record planned vaccine distribution by federal entity and through scheduled instalments. The Secretaría de Salud allocation schedule includes four deliveries on 30 September, 30 October, 20 November and 10 December 2014, while separate schedules identify October and November deliveries for listed entities.[9][14][15][2]
• Use population, registration and input tables to inform allocation. These include figures for people aged 60 years and over, pregnant women, health personnel, people living with HIV, and people with asthma, obesity, heart disease or diabetes.[11][12][8]
• Use births recorded through the Sistema de Información de Nacimientos, registered health personnel and registered people living with HIV as data inputs, although the excerpts do not define them as performance indicators or specify how they should be reported or assessed.[11][12]
• Maintain nominal censuses of children and enrolment lists for older-person programmes to identify people with incomplete vaccination schedules and organise follow-up searches.[13]
• Prioritise low-coverage areas and areas with deficient health services for intensive vaccination measures, but the source does not set a numerical coverage target or describe a method for measuring progress.[13]
• Review vaccination status whenever a person contacts a health establishment, including for consultations, emergencies, hospitalisation, surgery, routine checks or as an accompanying person, in order to reduce missed opportunities for immunisation.[13]
• Plan house-to-house activities using clearly delimited areas and maps available to vaccinators and supervisors, creating an operational basis for supervision but not a stated accountability system.[3]
• Provide annual revaccination because influenza strains change and antibody titres decline rapidly between nine and 12 months after vaccination.[6]
• Monitor expected adverse events following vaccination, including local pain, erythema or induration in approximately 20% of cases and infrequent systemic reactions, such as fever, myalgia and malaise, in fewer than 1% of adults. These reactions generally begin six to 12 hours after vaccination and last one or two days.[6]
• Recognise anaphylaxis as uncommon, reported at one in 4,000,000, and identify contraindications including prior anaphylaxis to egg or a vaccine component, a severe allergic response to influenza vaccine, and a history of Guillain-Barré syndrome.[6]
• Allow co-administration with other vaccines at different injection sites, or at any interval, and regard failure to provide eligible vaccines simultaneously as a missed vaccination opportunity.[6]

The supplied material does not specify formal monitoring indicators, baseline values, coverage targets, reporting frequencies, data-verification procedures, surveillance protocols, independent evaluation methods, responsible reporting bodies, sanctions, or other explicit accountability mechanisms.[9][2][8][13][6]

Costing & Financing

The material quantifies influenza vaccine inputs and delivery allocations but does not provide monetary costing, budget ceilings, unit prices, procurement expenditure, funding sources, financing arrangements, resource-mobilisation measures, funding gaps or economic assumptions.[1][2][10][8][13][6]

• Allocate 32,072,096 influenza vaccine doses across the Secretaría de Salud, Instituto Mexicano del Seguro Social, IMSS Oportunidades, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Secretaría de la Defensa Nacional and Petróleos Mexicanos for the 2014–2015 seasonal influenza vaccination plan.[1]
• Allocate 15,143,896 influenza vaccination supply units annually through the Secretaría de Salud schedule, divided equally into four instalments of 3,785,974 units.[2]
• Schedule the four equal supply deliveries for 30 September, 30 October, 20 November and 10 December.[2]
• Assign supplies by paediatric age group and dose category, including first and second doses for children aged 6–11 months, 12–35 months and 36–59 months, and annual booster quantities for the younger two groups.[10]
• Distribute total inputs across federal entities and population groups, rather than presenting those figures as monetary amounts. The tables headed partly “Insumo total” do not identify a currency or establish that the listed numbers are financial values.[11][12][8]
• Deploy resources through health establishments, community visits, mobile brigades, house-to-house vaccination, fixed posts and mobile posts, but no associated operational, cold-chain, staffing, transport, communication or campaign costs are specified.[13][3]
• Update vaccine composition annually in line with World Health Organization recommendations because of antigenic variation, without stating the financial implications of this requirement.[3]

Accordingly, the available quantitative information supports analysis of vaccine volumes and distribution timing only. It does not permit estimation of programme expenditure, affordability, cost per dose, financing adequacy, or an unfunded resource requirement.[1][2][10][8]